FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 04:06:44 07/06/2024 pm IST | ||
| 6.14 EUR | -6.12% |
|
| Current month | +26.34% | ||
| 1 month | +16.29% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 07/24/07 | 6.14 | -6.12% |
| 06/24/06 | 6.54 | +6.51% |
| 05/24/05 | 6.14 | +6.60% |
| 04/24/04 | 5.76 | +16.60% |
| 03/24/03 | 4.94 | +1.65% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 04:06 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB94SY |
| ISIN | DE000MB94SY3 |
| Date issued | 25/07/2023 |
| Strike | 11,019 p |
| Maturity | Unlimited |
| Parity | 2.86 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.02 € |
|---|---|
| Lowest since issue | 1.03 € |
| Spread | 0.02 € |
| Spread % | 0.31% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat
